One-month evaluation of safety and immunogenicity of a Vi-DT typhoid conjugate vaccine (Bio-TCV®) in Indonesian subjects 6 months to 45 years: A phase III randomized clinical trial

Background: Typhoid fever typically affects children and young adults and is a considerable cause of morbidity and mortality. Vaccination is the most effective preventive strategy to control typhoid fever in the short to medium term. However, in most endemic countries do not have a typhoid vaccine t...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Bernie Endyarni Medise, I. Gusti Ayu Trisna Windiani, Dominicus Husada, Rini Sekartini, Hartono Gunardi, Angga Wirahmadi, Dwiyanti Puspitasari, Leny Kartina, I. Gusti Agung Ngurah Sugitha Adnyana, I. Gusti Lanang Sidiartha, I. Made Dwi Lingga Utama, I. Ketut Agus Somia, Iris Rengganis, Sukamto Koesnoe, Hindra Irawan Satari, Soedjatmiko Soedjatmiko, Sri Rezeki Hadinegoro, Ismoedijanto Ismoedijanto, Parwati Setiono Basuki, Gatot Soegiarto, Soetjiningsih Soetjiningsih, Rini Mulia Sari, Mita Puspita, Aria Kekalih, Sreshta Mukhi, Vianca Samara Andhary, Novilia Sjafri Bachtiar, Sushant Sahastrabuddhe
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-08-01
Edice:	Vaccine: X
Témata:	Typhoid Vi-DT Typhoid conjugate vaccine
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2590136225000555
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!